Relation between TEL/AML1 and in vitro drug resistance in a cohort of 80 patients with childhood ALL with comparable risk factors
| Drug . | TEL/AML1-negative median (25th-75th) . | TEL/AML1-positive median (25th-75th) . | P . |
|---|---|---|---|
| Prednisolone | 2.30 (0.28-24.3) | 1.08 (0.22->250) | .924 |
| Dexamethasone | 0.08 (0.04->6.0) | 0.06 (0.02->6.0) | .455 |
| Vincristine | 0.55 (0.15-8.92) | 0.69 (0.49-1.65) | .635 |
| L-Asparaginase | 0.47 (0.02-1.25) | 0.04 (0.01-0.42) | .012 |
| Daunorubicin | 0.11 (0.07-0.28) | 0.10 (0.07-0.18) | .383 |
| 6-Thioguanine | 7.00 (5.06-10.05) | 5.80 (3.60-8.40) | .124 |
| Cytarabine | 0.40 (0.16-1.50) | 0.58 (0.34-1.44) | .181 |
| Etoposide | 1.37 (0.68-6.72) | 1.36 (0.68-2.26) | .825 |
| Ifosfamide | 3.89 (2.08-11.36) | 3.47 (1.86-4.39) | .666 |
| Drug . | TEL/AML1-negative median (25th-75th) . | TEL/AML1-positive median (25th-75th) . | P . |
|---|---|---|---|
| Prednisolone | 2.30 (0.28-24.3) | 1.08 (0.22->250) | .924 |
| Dexamethasone | 0.08 (0.04->6.0) | 0.06 (0.02->6.0) | .455 |
| Vincristine | 0.55 (0.15-8.92) | 0.69 (0.49-1.65) | .635 |
| L-Asparaginase | 0.47 (0.02-1.25) | 0.04 (0.01-0.42) | .012 |
| Daunorubicin | 0.11 (0.07-0.28) | 0.10 (0.07-0.18) | .383 |
| 6-Thioguanine | 7.00 (5.06-10.05) | 5.80 (3.60-8.40) | .124 |
| Cytarabine | 0.40 (0.16-1.50) | 0.58 (0.34-1.44) | .181 |
| Etoposide | 1.37 (0.68-6.72) | 1.36 (0.68-2.26) | .825 |
| Ifosfamide | 3.89 (2.08-11.36) | 3.47 (1.86-4.39) | .666 |
Median LC50 values for CD10+ B-lineage phenotype, older than 12 months, non-hyperdiploid (>50), non-Philadelphia translocation TEL/AML1-negative patients (n = 44) versus TEL/AML1-positive patients (n = 36). All LC50values are expressed as μg/mL, except for L-asparaginase (IU/mL).P values were determined by the Mann-Whitney U test.